Since the publication of the 2016 WHO guidelines, numerous studies have investigated additional clinical, radiologic, and molecular prognostic factors in an effort to further subclassify both IDH-wildtype and IDH-mutant gliomas and improve diagnostic and prognostic categories [26]. This evidence concerns the gene IDH2 and central nervous system cancer.